ClinicalTrials.gg
RecruitingNCT03740503GENIUSUpdated Jan 31, 2025

Genomic Investigation of Unusual Responders

An observational study in Cancer, Breast Cancer and Non-small Cell Lung Cancer, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-31.

Sponsored by University Health Network, Toronto · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Nov 2013; still recruiting 13 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

Studies have shown that tumors from the same patient may respond very differently to the same therapeutic agents. This study aims to investigate the genetic basis of tumors that respond abnormally well or poorly to therapeutic agents in an effort to understand the fundamental genetic basis of this response. The present protocol seeks to retrospectively perform Exome, next-generation (DNA) sequencing and/or other molecular techniques on tumor samples to identify the genetic basis of a patient's exceptional response to chemotherapy.

02

Conditions studied

  • Cancer
  • Breast Cancer
  • Non-small Cell Lung Cancer
  • Colorectal Cancer
  • Genitourinary Cancer
  • Gynecological Cancer
  • Upper Aerodigestive Tract Cancer
  • Pancreatobiliary Gastrointestinal Cancer
  • Melanoma (Skin)
  • Rare Cancer
  • Carcinoma of Unknown Primary

Keywords

  • Cancer
  • Breast Cancer
  • Non- small Cell Lung Cancer
  • Colorectal Cancer
  • Genitourinary Cancer
  • Gynecological Cancer
  • Upper Aerodigestive Tract Cancer
  • Pancreatobiliary Gastrointestinal Cancer
  • Melanoma Cancer
  • Rare Cancer
  • Unknown Primary Cancer
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 100 is below the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

University Health Network, Toronto is the lead sponsor of 1,441 studies on the registry; 298 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients enrolled who displayed exceptional response as well as those who were expected to respond favourably but displayed a poor outcome (e.g. drastic tumour growth or death) to their prescribed medication or treatment from a clinical trial.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient must have either an exceptionally good or poor response to treatment, as indicated by their treating physician.

    1. The exact definition of this is adaptable to the disease but a suggested guideline is a Complete Response, Partial Response or progression free interval of at least 6 months
    2. Exceptionally poor response includes patients who were expected to respond favourably to a treatment but instead responded poorly (e.g dramatic tumor growth or death)
  2. The patient must have sufficient archival tumor available for sequencing.
  3. Deceased patients will also be considered for analysis (up to 30 patients per year) if they meet at least one of the following requirements:

    a)) Patients who have stored within the UHN Laboratory Medicine Program who have had a consent waiver granted by the REB to access the tissue.

    b) Patients who have archival tissue banked for further research within the UHN Biospecimen Sciences Program

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Genomic Characterization of Tumor Samples

    Characterization of the genetic changes that may explain a tumor's exceptional response or disaster to therapeutc agents.

    Time frame: Through study completion, up to 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Madariaga A, Garg S, Bruce JP, Thiryayi S, Mandilaras V, Rath P, Oza AM, Dhani NC, Cescon DW, Lee YC, Chen E, Wang L, Clarke B, Lheureux S. Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer. Gynecol Oncol. 2020 Nov;159(2):539-545. doi: 10.1016/j.ygyno.2020.08.032. Epub 2020 Sep 8. PubMed 32912664 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2013 (actual). Primary completion is estimated for Nov 2025, 144 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2018
First posted
Nov 14, 2018
StartActual
Nov 1, 2013
Primary completionEst.
Nov 2025
CompletionEst.
Nov 2025
Last update
Jan 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03740503
Responsible party
Sponsor
First posted
Nov 14, 2018
Start date
Nov 1, 2013
Primary completion
Nov 2025 (estimated)
Completion
Nov 2025 (estimated)
Last update
Jan 31, 2025

Study contacts

Celeste Yu
Contact
celeste.yu@uhn.ca
416-946-4501 ext. 5281
Elizabeth Shah
Contact
elizabeth.shah@uhn.ca
416-946-4501 ext. 3833
David Cescon, MD
principal investigator · Princess Margaret Cancer Centre

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion